We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+14.94%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$112M
AUM Growth
+$11.4M
Cap. Flow
-$5.75M
Cap. Flow %
-5.12%
Top 10 Hldgs %
46.21%
Holding
94
New
5
Increased
13
Reduced
15
Closed
17

Top Buys

Rank Stock Value
1
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$4.27M
2
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$3.99M
3
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$1.68M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$1.45M
5
LOXO
Loxo Oncology, Inc
LOXO
+$1.34M

Top Sells

Rank Stock Value
1
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$4.35M
2
ACHN
Achillion Pharmaceuticals
ACHN
+$2.22M
3
OTIC
Otonomy, Inc.
OTIC
+$1.99M
4
XNPT
XENOPORT, INC.
XNPT
+$1.63M
5
PLX icon
Protalix BioTherapeutics
PLX
+$1.41M

Sector Composition

Rank Sector Weight
1 Healthcare 76.52%
2 Financials 0.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGNT
51
DELISTED
Cogentix Medical, Inc.
CGNT
$454K 0.4%
351,781
– –
TNDM icon
52
Tandem Diabetes Care
TNDM
$1.34B
$432K 0.39%
3,655
– –
CYTK icon
53
Cytokinetics
CYTK
$10.5B
$418K 0.37%
+40,000
New +$392K
BLUE
54
DELISTED
bluebird bio
BLUE
$385K 0.34%
463
– –
TENX icon
55
Tenax Therapeutics
TENX
$363M
$261K 0.23%
2
-1
-33% -$104K
GYRE icon
56
Gyre Therapeutics
GYRE
$641M
$222K 0.2%
630
– –
CRDC
57
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$216K 0.19%
140,276
– –
MBAI
58
Check-Cap
MBAI
$8.19M
$206K 0.18%
455
-3
-0.7% -$1.8K
RIOT icon
59
Riot Platforms
RIOT
$7.63B
$181K 0.16%
74,350
-6,950
-9% -$17K
GNVC
60
DELISTED
GenVec, Inc.
GNVC
$176K 0.16%
9,580
– –
TRVN
61
DELISTED
Trevena, Inc.
TRVN
$155K 0.14%
24
– –
SRRA
62
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$150K 0.13%
250
+37
+17% +$25K
AKTX
63
Akari Therapeutics
AKTX
$13.8M
$121K 0.11%
10
-23
-70% -$342K
ALPN
64
DELISTED
Alpine Immune Sciences Inc
ALPN
$116K 0.1%
3,750
– –
GLMD icon
65
Galmed Pharmaceuticals
GLMD
$5.13M
$91K 0.08%
67
+34
+103% +$54.3K
ETRM
66
DELISTED
EnteroMedics Inc.
ETRM
$65K 0.06%
476
– –
ATRS
67
DELISTED
Antares Pharma, Inc.
ATRS
$54K 0.05%
45,000
– –
CVM icon
68
CEL-SCI Corp
CVM
$20.3M
$47K 0.04%
170
-16
-9% -$6.24K
CHEKW
69
DELISTED
Check-Cap Ltd. Series A Warrant
CHEKW
$38K 0.03%
53,763
-1,237
-2% -$1.17K
AMGN icon
70
Amgen
AMGN
$208B
– –
-3,700
Closed -$512K
ATNM icon
71
Actinium Pharmaceuticals
ATNM
$26.3M
– –
-3,000
Closed -$159K
CRBP icon
72
Corbus Pharmaceuticals
CRBP
$166M
– –
-1,667
Closed -$79K
GILD icon
73
Gilead Sciences
GILD
$162B
– –
-5,700
Closed -$560K
PLX icon
74
Protalix BioTherapeutics
PLX
$191M
– –
-119,319
Closed -$1.41M
ICPT
75
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-2,430
Closed -$403K
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q4 2015 Portfolio in Review

As of Q4 2015, DAFNA Capital Management held 94 positions worth $112M, up 11% from $101M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

DAFNA Capital Management withdrew a net $5.75M in Q4 2015, closing 17 positions and reducing 15 holdings. Its most notable exit was ZS PHARMA INC COMS TK (DE), an estimated $4.35M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 75% a quarter earlier, followed by Financials.

Against the trend, DAFNA Capital Management opened a new position in CTI BioPharma Corp. (DE) Common Stock worth $3.93M.

  • DAFNA Capital Management's largest Q4 2015 buy was CTI BioPharma Corp. (DE) Common Stock: 319,538 shares worth $3.93M.
  • DAFNA Capital Management added most to Marinus Pharmaceuticals, Inc in Q4 2015, an estimated $3.99M increase.
  • DAFNA Capital Management's biggest Q4 2015 reduction was Achillion Pharmaceuticals, cutting an estimated $2.22M.
  • DAFNA Capital Management fully exited ZS PHARMA INC COMS TK (DE) in Q4 2015, selling an estimated $4.35M.
  • DAFNA Capital Management's ten largest holdings make up 46% of its $112M portfolio in Q4 2015.
  • DAFNA Capital Management opened 5 new positions and closed 17 in Q4 2015.
  • DAFNA Capital Management's portfolio value rose 11% quarter-over-quarter to $112M.

Based on DAFNA Capital Management's 13F filing for Q4 2015, filed 12 Feb 2016.